Login / Signup

Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.

Sara Jane CromerKristin M D'SilvaElaine W YuJoan LandonRishi J DesaiSeoyoung C Kim
Published in: Journal of general internal medicine (2021)
Rates of denosumab use outpaced growth of all other bone-directed therapies over the past decade. Treatment rates after osteoporotic fractures were low and declined over time, highlighting major failings in osteoporosis treatment in the US.
Keyphrases
  • bone mineral density
  • postmenopausal women
  • body composition
  • combination therapy
  • giant cell